Evidence map›Paper›PMID 40859322›Full record

ArticleAnnals of general psychiatry2025

Feasibility and structure of a state hospital botulinum neurotoxin clinic for clozapine-induced sialorrhea.

Ai-Li W Arias, Michael A Cummings, George J Proctor, Jonathan M Meyer

Abstract read
In one paragraph

Article in Annals of general psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ai-Li W AriasDepartment of Psychiatry and Neuroscience, University of California, Riverside, SOM Education Building, 900 University Avenue, Riverside, CA, 92521, USA. Aili.Arias@dsh.ca.gov.
Michael A CummingsDepartment of Psychiatry and Neuroscience, University of California, Riverside, SOM Education Building, 900 University Avenue, Riverside, CA, 92521, USA.
George J ProctorDepartment of Psychiatry and Neuroscience, University of California, Riverside, SOM Education Building, 900 University Avenue, Riverside, CA, 92521, USA.
Jonathan M MeyerPsychopharmacology Resource Network, Clinical Operations Division, California Department of State Hospitals (DSH), Allenby Building, 1215 O Street, Sacramento, CA, 95814, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clozapine is uniquely effective for treatment-resistant schizophrenia, treatment-resistant mania, and for aggression, suicide, or psychogenic polydipsia related to schizophrenia. Among its adverse effects, sialorrhea is an important barrier to clozapine treatment. Topical anticholinergic medications show limited efficacy, while systemic anticholinergics carry elevated risks of constipation, bowel impaction, or ileus. A superior treatment option for clozapine-induced sialorrhea exists in the form of periodic injection of major salivary glands with botulinum neurotoxin. This paper describes the feasibility and logistical issues involved in establishing a botulinum treatment clinic within a forensic psychiatric hospital. Critical elements in establishing a successful botulinum clinic for treatment of sialorrhea include adequate hospital administrative support, sufficient nursing staff, clinician injection training, education of treating psychiatrists regarding the availability and effectiveness of botulinum treatment for sialorrhea, and development of a clinic protocol, including procedural elements and relevant rating scales. Finally, botulinum treatment was evaluated to be cost-effective.

Indexed as

Botulinum neurotoxinBotulinum toxinClinicClozapineDroolingHypersalivationSialorrhea

Identifiers

PMID40859322
PMCPMC12382142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.